Aarti Drugs Ltd.

₹352.7

6.3 (1.8%)

AARTIDRUGS Share Price

Pharmaceuticals & Biotechnology

As on April 2, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 3,235 Cr

P/E Ratio19.14

Dividend Yield0.03 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	338.13	Bullish
10-DMA	337.56	Bullish
20-DMA	344.33	Bullish
50-DMA	362.25	Bearish
100-DMA	389.94	Bearish
200-DMA	441.52	Bearish

Historical Performance

1 Year

3 Years

4.4%

5 Years

-50.9%

10 Years

205.4%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	23,870	25,286	27,160	24,886	21,548
Total Expenditure	20,968	22,077	24,066	21,560	17,144
Other Income	164	40	22	113	45
Operating Profit	3,066	3,249	3,116	3,439	4,449
Interest	390	379	371	239	262
Depreciation	558	514	503	500	499
Profit Before Tax	2,118	2,355	2,242	2,700	3,690
Consolidated Net Profit	1,682	1,714	1,663	2,050	2,804
Adjusted EPS	18	19	18	22	30

Compounded Sales Growth

10 Years:16.8

5 Years:5.7

3 Years:-0.8

TTM:-1.1

Compounded Profit Growth

10 Years:16.8

5 Years:3.5

3 Years:-3.9

TTM:-0.4

Stock Price CAGR

10 Years:11.8

5 Years:-13.3

3 Years:1.1

TTM:1.2

Return on Equity

10 Years:7.1

5 Years:30.1

3 Years:18

last year:18.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	913	919	926	926	932
Total Reserves	12,777	11,896	10,998	9,438	8,202
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	3,684	3,549	2,793	2,316	2,572
Other Current Liabilities	1,447	1,512	1,001	1,113	1,054
Short Term Borrowings	2,718	2,147	3,605	3,563	1,572
Total Liabilities	25,747	24,324	24,214	22,080	17,660
Capital Work in Progress	2,741	2,252	1,868	767	193
Long Term Loans & Advances	176	197	242	284	73
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	1,028	1,176	987	945	743
Total Current Assets	13,384	13,207	14,918	13,934	10,568
Total Assets	25,747	24,324	24,214	22,080	17,660
Adjusted Book Value	150	139	129	112	98

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 19.14, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of 1.1%, indicating poor shareholder returns.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹3066 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹23870 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1012051.6

No. of Shares: 2869 (Approx)

Performance:1.2%

P/L: ₹12051.6

NIFTY Performance: -2.3%

1 day Top Gainers